NEWS & EVENTS

Latest news and upcoming events

09 Sep 2021

Ysios Capital achieves Certification under the Diversity VC Standard

Upcoming events
  • Jefferies London Healthcare Conference
    16 November – 18 Nov. 2021,
    London

  • LSX World Congress
    8 February – 9 February 2022,
    London

Ysios Capital Partners participates in Biovex’s $70million final closing

Woburn, MA, November 10, 2009 ‐‐ BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March.

Laia Crespo joins Ysios Capital Partners as Investment Manager

Main responsibilities of Laia Crespo will include the identification and assessment of investment and disinvestment opportunities from the scientific and business perspectives

Ysios Capital Partners participates in the $36million . €25million Series B Financing of Endosense

Barcelona – September 1, 2009 – Endosense, a medical technology company focused on improving efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing.

Ysios Capital Partners participates in the $36million . €25million Series B Financing of Endosense

Barcelona – September 1, 2009 – Endosense, a medical technology company focused on improving efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing.

Ysios Capital Partners announces the first closing of the largest Spanish biotech fund at €67million

The fund will be invested in 10 to 12 biotechnology companies in the field of human health.

Raúl Martín-Ruiz joins Ysios Capital Partners as Investment Manager

Main responsibilities of Martín-Ruiz will be to analyze and evaluate the feasibility of the target companies of the fund from a scientific and business point of view.

Paula Olazábal joins Ysios Capital Partners as investment manager

Her appointment comes along with the new stage of the venture capital firm specialized in biotech, which is preparing the first closing of Ysios BioFund I.

Ysios Capital Partners names Marc Casellas as Chief Financial Officer

Ysios has created this position to manage the increased activity expected as the initial capital subscription of its first fund, Ysios BioFund I, draws to a close

Ysios Capital Partners announces the imminent first closing of the largest Spanish venture capital fund in the biotech sector

The company anticipates a first closing of around EUR 60 million in brief.

Ysios co-leads €27,2million Series B financing of stem cell company Cellerix

Barcelona, September 20, 2007. ‐ Cellerix, a biopharmaceutical company leader in the clinical development and production of innovative medicines based on adult stem cells, has closed an oversubscribed Series B financing round for €27.2M.

Newsletter

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.